Expression of Vascular Endothelial Growth Factor Receptors in Benign Vascular Lesions of the Orbit: A Case Series

详细信息    查看全文

• 作者：Elizabeth A. Atchison ; MD¹ ; ^{atchison.elizabeth@mayo.edu" class="auth_mail" title="E-mail the corresponding author} ; James A. Garrity ; MD¹ ; Francisco Castillo ; MD² ; Steven J. Engman ; MD ; PhD³ ; Steven M. Couch ; MD⁴ ; Diva R. Salomã ; o ; MD¹ ; ⁵
• 关键词：VEGF ; vascular endothelial growth factor ; VEGFR1 ; vascular endothelial growth factor receptor type 1 ; VEGFR2 ; vascular endothelial growth factor receptor type 2 ; VEGFR3 ; vascular endothelial growth factor receptor type 3
• 刊名：Ophthalmology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：123
• 期：1
• 页码：209-213
• 全文大小：986 K

文摘

Vascular lesions of the orbit, although not malignant, can cause morbidity because of their location near critical structures in the orbit. For the same reason, they can be challenging to remove surgically. Anti-vascular endothelial growth factor (VEGF) drugs are increasingly being used to treat diseases with prominent angiogenesis. Our study aimed to determine to what extent VEGF receptors and their subtypes are expressed on selected vascular lesions of the orbit.

Design

Retrospective case series of all orbital vascular lesions removed by one of the authors (JAG) at the Mayo Clinic.

Participants

A total of 52 patients who underwent removal of vascular orbital lesions.

Methods

The pathology specimens from the patients were retrieved, their pathologic diagnosis was confirmed, demographic and clinical information were gathered, and sections from vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGFR3).

Main Outcome Measures

The existence and pattern of staining with VEGF and its subtypes on these lesions.

Results

There were 28 specimens of venous malformations, 4 capillary hemangiomas, 7 lymphatic malformations, and 6 lymphaticovenous malformations. All samples stained with VEGF, 55% stained with VEGFR1, 98% stained with VEGFR2, and 96% stained with VEGFR3. Most (94%) of the VEGFR2 staining was diffuse.

Conclusions

Most orbital vascular lesions express VEGF receptors, which may suggest a future target for nonsurgical treatment.